Glioblastoma, Adult Clinical Trial
Official title:
Multicenter Phase II Study Evaluating the Efficacy of Radiotherapy With Modulation Intensity and Integrated Boost (SIB-IMRT) at the Dose of 80Gy, Associated With Chemotherapy by Temozolomide in the Treatment of Adult Glioblastomas
Glioblastoma (GBM) is the most aggressive and most frequent brain tumour. Approximately four people per 100,000 inhabitants are diagnosed with this disease every year. The standard treatment comprises surgical resection (whenever possible), normofractionated radiotherapy at a dose of 60Gray (Gy) and temozolomide (TMZ). Median overall survival in these patients is 14.6 months [13.2-16.8]. In a previous phase I clinical trial, dose escalation tolerance using simultaneous-integrated boost intensity-modulated radiation therapy (SIB-IMRT) technic has been evaluated. The investigator demonstrated that SIB-IMRT until a dose of 80Gy in 32 daily fractions, associated with TMZ is feasible and well tolerated by patients with glioblastoma. The aim of this present phase II clinical trial is to evaluate the overall survival at 18 months for patients with glioblastoma receiving TMZ, according to standard protocol, associated to radiotherapy delivered at 80Gy using SIB-IMRT technic. The first planning target volume (PTV), including oedema and tumour highlighted on T2 flair magnetic resonance imaging (MRI) sequences, will receive 60.8Gy in 32 daily fractions. The second PTV, including tumour highlighted on T1 MRI sequences, will receive 80.0Gy in 32 daily fractions. Secondary objectives are tolerance, survival free progression and quality of live evaluations. Sixty seven patients will be enrolled in this present trial.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03291977 -
Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME)
|
Phase 3 | |
| Active, not recruiting |
NCT03665545 -
Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma
|
Phase 1/Phase 2 | |
| Terminated |
NCT03714334 -
DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma
|
Phase 1 | |
| Recruiting |
NCT03277638 -
Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)
|
Phase 1/Phase 2 | |
| Completed |
NCT03158389 -
NCT Neuro Master Match - N²M² (NOA-20)
|
Phase 1/Phase 2 | |
| Completed |
NCT03522298 -
Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma
|
Phase 2 | |
| Recruiting |
NCT03213002 -
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
|
Phase 1/Phase 2 | |
| Completed |
NCT03232424 -
NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma
|
Phase 1 | |
| Active, not recruiting |
NCT04116658 -
First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma
|
Phase 1/Phase 2 | |
| Completed |
NCT03618667 -
GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification
|
Phase 2 | |
| Recruiting |
NCT04128774 -
Function and Composition of Regulatory B Cells in Participants With Glioblastoma
|
||
| Completed |
NCT03744026 -
Safety and Efficacy of Transient Opening of the Blood-brain Barrier (BBB) With the SonoCloud-9
|
Phase 1/Phase 2 | |
| Completed |
NCT04610229 -
Safety of IMRT Treatment With Inhomogeneous Dose in Patients With Relapsed High-grade Gliomas.
|
N/A | |
| Active, not recruiting |
NCT02974738 -
A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)
|
Phase 1 | |
| Recruiting |
NCT03025893 -
A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme
|
Phase 2/Phase 3 | |
| Completed |
NCT03075514 -
Ketogenic Diets as an Adjuvant Therapy in Glioblastoma
|
N/A |